Abstract
Autoregulation of renal blood flow and glomerular filtration rate is an essential function of the renal microcirculation. While the existence of this phenomenon has been known for many years, the exact mechanisms that underlie this regulatory system remain poorly understood. The work of many investigators has provided insights into many aspects of the autoregulatory mechanism, but many critical components remain elusive. This review is intended to update the reader on the role of P2 purinoceptors as a postulated mechanism responsible for renal autoregulatory resistance adjustments. It will summarize recent advances in normal function and it will touch on more recent ideas regarding autoregulatory insufficiency in hypertension and inflammation. Current thoughts on the nature of the mechanosensor responsible for myogenic behavior will be also be discussed as well as current thoughts on the mechanisms involved in ATP release to the extracellular fluid space.
Keywords: ATP, adenosine, afferent arterioles, P2 receptors, connexins, myogenic behavior, tubuloglomerular feedback.
Current Vascular Pharmacology
Title:P2 Receptors in Renal Autoregulation
Volume: 12 Issue: 6
Author(s): Zhengrong Guan, Robert C. Fellner, Justin Van Beusecum and Edward W. Inscho
Affiliation:
Keywords: ATP, adenosine, afferent arterioles, P2 receptors, connexins, myogenic behavior, tubuloglomerular feedback.
Abstract: Autoregulation of renal blood flow and glomerular filtration rate is an essential function of the renal microcirculation. While the existence of this phenomenon has been known for many years, the exact mechanisms that underlie this regulatory system remain poorly understood. The work of many investigators has provided insights into many aspects of the autoregulatory mechanism, but many critical components remain elusive. This review is intended to update the reader on the role of P2 purinoceptors as a postulated mechanism responsible for renal autoregulatory resistance adjustments. It will summarize recent advances in normal function and it will touch on more recent ideas regarding autoregulatory insufficiency in hypertension and inflammation. Current thoughts on the nature of the mechanosensor responsible for myogenic behavior will be also be discussed as well as current thoughts on the mechanisms involved in ATP release to the extracellular fluid space.
Export Options
About this article
Cite this article as:
Guan Zhengrong, Fellner C. Robert, Beusecum Van Justin and Inscho W. Edward, P2 Receptors in Renal Autoregulation, Current Vascular Pharmacology 2014; 12 (6) . https://dx.doi.org/10.2174/15701611113116660152
DOI https://dx.doi.org/10.2174/15701611113116660152 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Dissolution Enhancement of Eplerenone using Solvent Melt Method
Drug Delivery Letters Cardiovascular Effects of Liraglutide
Current Hypertension Reviews The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial (Thematic Issue: Cardiovascular Prevention: Can We Do Any Better?)
Current Pharmaceutical Design Current Place of Beta-Blockers in the Treatment of Hypertension
Current Vascular Pharmacology Aging and DNA Methylation
Current Chemical Biology Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets Somatostatin and its Analogs
Current Drug Targets Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome
Current Pharmaceutical Design Telomeres and their Role in Aging and Longevity
Current Vascular Pharmacology Docking-based 3D-QSAR Studies of Phosphodiesterase 9A Inhibitors
Letters in Drug Design & Discovery Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry Editorial [ UCTD and Unfinished Business ]
Current Rheumatology Reviews Estimated Arterial Stiffness and Prediction of Vascular Aging: The Rising of a New Era
Current Pharmaceutical Design Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued)